

## Supplementary Online Content

Hu X, Chehal PK, Kaplan C, et al. Characterization of clinical symptoms by race among women with early-stage, hormone receptor–positive breast cancer before starting chemotherapy. *JAMA Netw Open*. 2021;4(6):e2112076.  
doi:10.1001/jamanetworkopen.2021.12076

**eFigure.** Sample Selection Flow Chart

**eTable 1.** List of Individual Symptoms Used for Four Compound Scores

**eTable 2.** Patient Characteristics of Medicare Subsample


**eTable 3.** Patient Characteristics of Patients Who Received Surgery Before Chemotherapy and Had a PCM Report Between Surgery and Chemotherapy Initiation

**eTable 4.** Oaxaca Decomposition of Race Differences in Symptom Index Scores of Medicare Subsample

**eTable 5.** Oaxaca Decomposition of Race Differences in Symptom Index Scores of Patients Who Received Surgery Before Chemotherapy and Had a PCM Report Between Surgery and Chemotherapy Initiation

This supplementary material has been provided by the authors to give readers additional information about their work.

**eFigure.** Sample Selection Flow Chart



**eTable 1.** List of Individual Symptoms Used for Four Compound Scores

Compound Score	General Physical Symptoms	Treatment Adverse Effects	Acute Distress	Despair
<b>Individual Item</b>	1. Fatigue, tiredness, or weakness	1. Change in weight	1. I cry a lot or feel like crying	1. I feel hopeless
	2. Rash or dry skin or itching	2. Hair loss	2. I am worried	2. I have lost interest in people that I used to want to be around
	3. Trouble focusing or concentrating	3. Nausea or vomiting	3. I feel nervous, tense, or anxious	3. I feel helpless
	4. Daytime sleepiness	4. Dry mouth	4. I am sad or depressed	4. I think I would be better off dead
	5. Physical pain	5. Change in the taste of food		5. I feel guilty
	6. Sweating	6. Trouble with bowel movements (diarrhea or constipation)		6. I have lost interest in things that I used to want to do
	7. Trouble breathing or coughing	7. Sore throat or trouble swallowing		7. I feel worthless
	8. Reduced sexual enjoyment, interest, or performance	8. Change in appetite		
	9. Trouble sleeping			
	10. Problems with urination			
	11. Numbness or tingling			

**eTable 2.** Patient Characteristics of Medicare Subsample

Characteristics	Patients, No. (%)			P Value <sup>a</sup>
	Total (N=147)	Black (n=32)	White (n=115)	
Age, y				
Mean (SD)	70.8 (8.5)	65.3 (11.1)	72.3 (6.9)	0.001
Median (IQR)	71.0 (69.0- 76.0)	69.0 (57.5- 72.5)	72.0 (69.0- 77.0)	
Stage at diagnosis				0.81
Stage I	40 (27.2%)	9 (28.1%)	31 (27.0%)	
Stage II	67 (45.6%)	13 (40.6%)	54 (47.0%)	
Stage III	40 (27.2%)	10 (31.3%)	30 (26.1%)	
Comorbidities				0.26
No comorbidity	56 (38.1%)	11 (34.4%)	45 (39.1%)	
One comorbidity	44 (29.9%)	7 (21.9%)	37 (32.2%)	
More than 1 comorbidity	47 (32.0%)	14 (43.8%)	33 (28.7%)	
Household income at the neighborhood level, \$				
Mean (SD)	48643 (23271)	31170 (14984)	53505 (22868)	<.001
Median (IQR)	40221 (32531-64209)	29193 (25989-34128)	50701 (34072-64582)	<.001
Adults with high school degree at the neighborhood level, %				
Mean (SD)	82.5 (9.1)	74.6 (7.0)	84.7 (8.4)	<.001
Median (IQR)	82.7 (75.6- 90.7)	75.6 (70.6- 76.8)	86.0 (77.8- 91.5)	<.001
State of residence				0.61
Arkansas	7 (4.8%)	1 (3.1%)	6 (5.2%)	
Mississippi	55 (37.4%)	15 (46.9%)	40 (34.8%)	
Tennessee	82 (55.8%)	16 (50.0%)	66 (57.4%)	
Other	3 (2.0%)	0 (0.0%)	3 (2.6%)	
Time between survey and chemotherapy initiation, mean (SD), d	6.7 (9.9)	5.6 (8.9)	7.0 (10.2)	0.51
Time between diagnosis and chemotherapy initiation, mean (SD), d	69.2 (34.3)	65.3 (41.7)	70.3 (32.1)	0.47
Any Severity Symptoms, mean (SD), No.	12.5 (10.0)	12.4 (10.8)	12.5 (9.8)	0.97

Abbreviation: IQR=Interquartile Range; SD=Standard Deviation

<sup>a</sup> The t test was used for mean comparisons, the Wilcoxon rank-sum test was used for median comparisons, and the  $\chi^2$  test or the Fisher exact test 2 were used for categorical measures

**eTable 3.** Patient Characteristics of Patients Who Received Surgery Before Chemotherapy and Had a PCM Report Between Surgery and Chemotherapy Initiation

Characteristics	Patients, No. (%)			P Value <sup>a</sup>
	Total (N=658)	Black (n=210)	White (n=448)	
Age, y				
Mean (SD)	56.2 (11.9)	53.0 (10.8)	57.7 (12.1)	<.001
Median (IQR)	56.0 (48.0, 65.0)	53.0 (46.0, 61.0)	57.0 (49.0, 67.0)	<.001
Stage at diagnosis				0.075
Stage I	238 (36.2%)	63 (30.0%)	175 (39.1%)	
Stage II	304 (46.2%)	105 (50.0%)	199 (44.4%)	
Stage III	116 (17.6%)	42 (20.0%)	74 (16.5%)	
Household income at the neighborhood level, \$				
Mean (SD)	52432 (23790)	41177 (18923)	57708 (24021)	<.001
Median (IQR)	48234 (33295-64985)	34128 (29066-51295)	51656 (36993-70541)	<.001
Adults with high school degree at the neighborhood level, %				
Mean (SD)	84.6 (9.0)	81.0 (8.5)	86.3 (8.7)	<.001
Median (IQR)	86.0 (76.9-92.8)	79.6 (75.6-87.1)	87.2 (79.7-94.3)	<.001
State or residence				<.001
Arkansas	25 (3.8%)	5 (2.4%)	20 (4.5%)	
Mississippi	170 (25.8%)	34 (16.2%)	136 (30.4%)	
Tennessee	446 (67.8%)	170 (81.0%)	276 (61.6%)	
Other	17 (2.6%)	1 (0.5%)	16 (3.6%)	
Time between survey and chemotherapy initiation, Mean (SD), d	5.9 (8.6)	6.0 (8.8)	5.8 (8.5)	0.73
Time between diagnosis and chemotherapy initiation, mean (SD), d	73.7 (28.9)	79.5 (31.4)	71.1 (27.2)	0.001
Time between surgery and survey, mean (SD), d	42.1 (25.5)	45.5 (27.2)	40.5 (24.5)	0.019
Any Severity Symptoms, mean (SD), No.	11.7 (9.3)	12.0 (9.5)	11.6 (9.2)	0.61

Abbreviation: IQR=Interquartile Range; SD=Standard Deviation

<sup>a</sup> The t test was used for mean comparisons, the Wilcoxon rank-sum test was used for median comparisons, and the  $\chi^2$  test or the Fisher exact test 2 were used for categorical measures

**eTable 4.** Oaxaca Decomposition of Race Differences in Symptom Index Scores of Medicare Subsample

Symptom Index Scores	Patients, No.	Unadjusted mean (SE) composite score <sup>a</sup>		Crude net Difference (SE) in mean scores <sup>a</sup>	Explained Difference (SE) <sup>a</sup>	Unexplained Difference (SE) <sup>a</sup>
		White patients	Black patients			
<b>(A) Without Controlling for Comorbidities</b>						
General Physical Symptoms	147	44.6 (0.7) <sup>b</sup>	43.7 (1.7) <sup>b</sup>	0.9 (1.8)	-3.3 (1.3) <sup>b</sup>	4.2 (2.2)
Treatment Adverse Effects	146	44.5 (0.5) <sup>b</sup>	45.2 (1.2) <sup>b</sup>	-0.8 (1.3)	-1.0 (0.9)	0.2 (1.6)
Acute Distress	105	49.3 (1.3) <sup>b</sup>	45.7 (2.1) <sup>b</sup>	3.6 (2.5)	-3.3 (2.4)	6.9 (3.5) <sup>b</sup>
Despair	73	47.3 (1.2) <sup>b</sup>	46.5 (1.9) <sup>b</sup>	0.8 (2.2)	-6.1 (2.9) <sup>b</sup>	6.9 (3.7)
<b>(B) Controlling for Comorbidities</b>						
General Physical Symptoms	147	44.6 (0.7) <sup>b</sup>	43.7 (1.7) <sup>b</sup>	0.9 (1.9)	-3.8 (1.4) <sup>b</sup>	4.7 (2.2) <sup>b</sup>
Treatment Adverse Effects	146	44.5 (0.5) <sup>b</sup>	45.2 (1.2) <sup>b</sup>	-0.8 (1.3)	-1.4 (1.1)	0.6 (1.7)
Acute Distress	105	49.3 (1.3) <sup>b</sup>	45.7 (2.2) <sup>b</sup>	3.6 (2.5)	-3.3 (2.5)	6.9 (3.6)
Despair	73	47.3 (1.2) <sup>b</sup>	46.5 (2.0) <sup>b</sup>	0.8 (2.3)	-6.4 (3.1) <sup>b</sup>	7.2 (3.9)

<sup>a</sup> Robust SEs in parentheses. Analysis controlled for all covariates in the whole sample analysis as well as comorbidities (in panel B).

<sup>b</sup>  $P < 0.05$

**eTable 5.** Oaxaca Decomposition of Race Differences in Symptom Index Scores of Patients Who Received Surgery Before Chemotherapy and Had a PCM Report Between Surgery and Chemotherapy Initiation

Symptom Index Scores	Patients, No.	Unadjusted mean (SE) composite score <sup>a</sup>		Crude net Difference (SE) in mean scores <sup>a</sup>	Explained Difference (SE) <sup>a</sup>	Unexplained Difference (SE) <sup>a</sup>
		White patients	Black patients			
<b>(C) Without Controlling for Days from Surgery to Survey</b>						
General Physical Symptoms	658	44.7 (0.4) <sup>b</sup>	44.5 (0.6) <sup>b</sup>	0.1 (0.7)	-1.6 (0.5) <sup>b</sup>	1.7 (0.9) <sup>b</sup>
Treatment Adverse Effects	658	43.7 (0.2) <sup>b</sup>	44.7 (0.4) <sup>b</sup>	-0.9 (0.4) <sup>b</sup>	-0.6 (0.3) <sup>b</sup>	-0.3 (0.5)
Acute Distress	513	50.9 (0.6) <sup>b</sup>	48.3 (0.9) <sup>b</sup>	2.6 (1.1) <sup>b</sup>	-2.5 (0.7) <sup>b</sup>	5.0 (1.3) <sup>b</sup>
Despair	396	48.4 (0.5) <sup>b</sup>	47.8 (0.7) <sup>b</sup>	0.7 (0.9)	-2.0 (0.6) <sup>b</sup>	2.7 (1.1) <sup>b</sup>
<b>(D) Controlling for Days from Surgery to Survey</b>						
General Physical Symptoms	658	44.7 (0.4) <sup>b</sup>	44.5 (0.6) <sup>b</sup>	0.1 (0.7)	-1.6 (0.5) <sup>b</sup>	1.7 (0.9) <sup>b</sup>
Treatment Adverse Effects	658	43.7 (0.2) <sup>b</sup>	44.7 (0.4) <sup>b</sup>	-0.9 (0.4) <sup>b</sup>	-0.6 (0.3) <sup>b</sup>	-0.3 (0.5)
Acute Distress	513	50.9 (0.6) <sup>b</sup>	48.3 (0.9) <sup>b</sup>	2.6 (1.1) <sup>b</sup>	-2.4 (0.7) <sup>b</sup>	5.0 (1.3) <sup>b</sup>
Despair	396	48.4 (0.5) <sup>b</sup>	47.8 (0.8) <sup>b</sup>	0.7 (0.9)	-2.0 (0.6) <sup>b</sup>	2.7 (1.1) <sup>b</sup>

<sup>a</sup> Robust SEs in parentheses. Analysis controlled for all covariates in the whole sample analysis as well as time from surgery to survey (in panel D).

<sup>b</sup>  $P < 0.05$